Arvin Eskandari

Dr. Arvin Eskandari

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2017 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
KLKristine Laws Laws
Kristine Laws Laws
GBGanka Bineva‐Todd
Ganka Bineva‐Todd
AEArvin Eskandari
Arvin Eskandari
CLChunxin Lu
Chunxin Lu
NONicola O'Reilly
Nicola O'Reilly
Kogularamanan SuntharalingamKogularamanan Suntharalingam
Kogularamanan Suntharalingam

20 November 2024 in Journal of Colloid and Interface Science
Verified
Journal Article
Open access
YWYang Wang
Yang Wang
RFRachel L. Foulkes
Rachel L. Foulkes
Nikolaos PanagiotouNikolaos Panagiotou
Nikolaos Panagiotou
PMPanagiota Markopoulou
Panagiota Markopoulou
APAndrea Bistrović Popov
Andrea Bistrović Popov
RFRoss Forgan
Ross Forgan
Controllable surface modification of nanoparticulate drug delivery vectors is key to enhancing specific desirable properties such as colloidal stability, targeting, and stimuli-responsive cargo release. Metal-organic frameworks (MOFs) have been proposed as potential delivery devices, with surface modification achieved by various bioconjugate "click" reactions, including copper-catalysed and strain-promoted azide-alkyne cycloaddition. Herein, we show that photo-induced nitrile imine-mediated tetrazole-ene cycloaddition (NITEC) can be used to surface-modify tetrazole-appended Zr MOFs with maleimides, and vice versa, with the extent of this traceless surface functionalisation controlled by the length of photoirradiation. This "photoclick" surface modification protocol is exemplified by the decorating of carboplatin-loaded MOF-808 with galactose units to target asialoglycoprotein receptors of specific cancer cell types. Targeting towards HepG2 cells, which overexpress these receptors, is indicated by enhanced endocytosis and cytotoxicity in both two- and three-dimensional cell cultures compared to other cell lines. The study shows both the power of the NITEC protocol for functionalisation of MOFs, and also the benefits of carbohydrate targeting in drug delivery vectors, with scope for significant additional work diversifying the surface targeting units available for nanoparticle functionalisation under these mild, biocompatible "photoclick" conditions.

9 February 2017 in Inorganics
Verified
Journal Article
Open access
PDF file
PCPaul Cressey
Paul Cressey
AEArvin Eskandari
Arvin Eskandari
Kogularamanan SuntharalingamKogularamanan Suntharalingam
Kogularamanan Suntharalingam
Cancer stem cells (CSCs) are thought to be responsible for cancer relapse. CSCs are a subtype of cancer cells with the ability to differentiate, self-renew, and form secondary or tertiary tumors. Current cancer treatments—including chemotherapy, radiation, and surgery—effectively remove bulk cancer cells but are unable to eliminate CSCs. Here, we present the synthesis, characterization, and anti-CSC properties of a cobalt(III)–cyclam complex bearing two tolfenamic acid moieties, 3. Notably, 3 displays sub-micromolar potency towards breast CSCs and bulk breast cancer cells. Detailed mechanistic studies show that 3 is taken up readily by breast CSCs, enters the nucleus, causes DNA damage, and induces caspase-dependent apoptosis. Furthermore, 3 inhibits cyclooxygenase-2 (COX-2) expression in CSCs. The mechanism of action of 3 is similar to that of a naproxen-appended cobalt(III)–cyclam complex, 1 recently reported by our group. The advantage of 3 over 1 is that it has the potential to remove whole tumor populations (bulk cancer cells and CSCs) with a single dose.

4 September 2018 in Molecules
Verified
Journal Article
Open access
PDF file
TRTiffany K. Rundstadler
Tiffany K. Rundstadler
AEArvin Eskandari
Arvin Eskandari
SNSarah M. Norman
Sarah M. Norman
Kogularamanan SuntharalingamKogularamanan Suntharalingam
Kogularamanan Suntharalingam
Cancer stem cells (CSCs) are thought of as a clinically pertinent subpopulation of tumors, partly responsible for cancer relapse and metastasis. Research programs aimed at discovering anti-CSC agents have largely focused on biologics and purely organic molecules. Recently, we showed that a family of redox-active copper(II) complexes with phenanthroline-based ligands and nonsteroidal anti-inflammatory drugs (NSAIDs) such as indomethacin, are capable of potently and selectively killing breast CSCs. Herein we present analogous redox-inactive, zinc(II)-phenanthroline-indomethacin complexes with the ability to kill breast CSCs and bulk breast cancer cells with equal potency (in the submicro- or micromolar range). A single dose of the zinc(II) complexes could theoretically be administered to eliminate whole tumor populations. Excitingly, some of the zinc(II) complexes decrease the growth and viability of mammospheres to a comparable or higher degree than salinomycin, a compound known to effectively kill breast CSCs. As far as we are aware this is the first report to examine the anti-breast CSC activity of zinc(II)-containing compounds.

16 May 2020 in ChemBioChem
Verified
Journal Article
Closed access
PDF file
AEArvin Eskandari
Arvin Eskandari
MFMarie Flamme
Marie Flamme
ZXZhiyin Xiao
Zhiyin Xiao
Kogularamanan SuntharalingamKogularamanan Suntharalingam
Kogularamanan Suntharalingam

5 December 2017 in Angewandte Chemie
Verified
Journal Article
Open access
PDF file
KLKristine Laws Laws
Kristine Laws Laws
GBGanka Bineva‐Todd
Ganka Bineva‐Todd
AEArvin Eskandari
Arvin Eskandari
CLChunxin Lu
Chunxin Lu
NONicola O'Reilly
Nicola O'Reilly
Kogularamanan SuntharalingamKogularamanan Suntharalingam
Kogularamanan Suntharalingam
The breast cancer stem cell (CSC) and bulk breast cancer cell potency of a series of metallopeptides containing dichloro(1,10‐phenanthroline)copper(II) and various organelle‐targeting peptide sequences is reported. The mitochondria‐targeting metallopeptide 1 exploits the higher mitochondrial load in breast CSCs over the corresponding non‐CSCs and the vulnerability of breast CSCs to mitochondrial damage to potently and selectively kill breast CSCs. Strikingly, 1 reduces the formation and size of mammospheres to a greater extent than salinomycin, an established CSC‐potent agent. Mechanistic studies show that 1 enters CSC mitochondria, induces mitochondrial dysfunction, generates reactive oxygen species (ROS), activates JNK and p38 pathways, and prompts apoptosis. To the best of our knowledge, 1 is the first metallopeptide to selectivity kill breast CSCs in vitro.